|
Guselkumab Clinical Trials
9 actively recruiting trials across 7 locations
▲ +1 trial since August 2026
Also known as: CNTO1959, TREMFYA, Tremfya
Pipeline
Phase 2: 1Phase 3: 2Phase 4: 4
Top Sponsors
- University of California, San Diego2
- NYU Langone Health2
- Janssen Research & Development, LLC2
- University of Pennsylvania1
- Johnson & Johnson Private Limited1
Indications
- Arthritis9
- Psoriatic Arthritis3
- Arthritis, Psoriatic3
- Psoriasis3
- Colitis, Ulcerative2
Other2 trials
La Jolla, California1 trial
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
University of California, San Diego
San Diego, California1 trial
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
University of California, San Diego
N/A
Loxahatchee Groves, Florida1 trial
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Family Arthritis Center
Phase 3
Atlanta, Georgia1 trial
Phase 3
Boston, Massachusetts1 trial
Multi-Center PAMPA Study
Brigham and Women's Hospital
Phase 4
New York, New York1 trial
Chapel Hill, North Carolina1 trial
A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
University of North Carolina at Chapel Hill
Phase 4
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.